These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 29514613)
41. The importance of decision intent within descriptions of pragmatic trials. Nicholls SG; Zwarenstein M; Hey SP; Giraudeau B; Campbell MK; Taljaard M J Clin Epidemiol; 2020 Sep; 125():30-37. PubMed ID: 32422248 [TBL] [Abstract][Full Text] [Related]
42. Pragmatic randomized clinical trials: a proposal to enhance evaluation of new cancer therapies with early signs of exceptional activity. Koehler M; Donnelly ET; Kalanovic D; Dagher R; Rothenberg ML Ann Oncol; 2016 Jul; 27(7):1342-8. PubMed ID: 27029709 [No Abstract] [Full Text] [Related]
43. The great divide: a qualitative investigation of factors influencing researcher access to potential randomised controlled trial participants in mental health settings. Patterson S; Kramo K; Soteriou T; Crawford MJ J Ment Health; 2010 Dec; 19(6):532-41. PubMed ID: 21121823 [TBL] [Abstract][Full Text] [Related]
44. Dissemination of trial results to participants in phase III pragmatic clinical trials: an audit of trial investigators intentions. Raza MZ; Bruhn H; Gillies K BMJ Open; 2020 Feb; 10(1):e035730. PubMed ID: 32014881 [TBL] [Abstract][Full Text] [Related]
45. Conducting rapid, relevant research: lessons learned from the My Own Health Report project. Glasgow RE; Kessler RS; Ory MG; Roby D; Gorin SS; Krist A Am J Prev Med; 2014 Aug; 47(2):212-9. PubMed ID: 24953520 [TBL] [Abstract][Full Text] [Related]
49. Study characteristics impacted the pragmatism of randomized controlled trial published in nursing: a meta-epidemiological study. Devos F; Foissac F; Bouazza N; Ancel PY; Tréluyer JM; Chappuy H J Clin Epidemiol; 2019 Dec; 116():18-25. PubMed ID: 31374332 [TBL] [Abstract][Full Text] [Related]
50. Remarkable international variability in reasons for ineligibility and non-participation in the GLORIA trial. Hartman L; Bos R; Buttgereit F; Güler-Yuksel M; Ionescu R; Kok MR; Lems WF; Micaelo M; Opris-Belinski D; Pusztai A; Santos E; Da Silva J; Szekanecz Z; Zeiner K; Zhang D; Boers M Scand J Rheumatol; 2019 Jul; 48(4):340-341. PubMed ID: 31132016 [No Abstract] [Full Text] [Related]
51. Principles and procedures for data and safety monitoring in pragmatic clinical trials. Simon GE; Shortreed SM; Rossom RC; Penfold RB; Sperl-Hillen JAM; O'Connor P Trials; 2019 Dec; 20(1):690. PubMed ID: 31815644 [TBL] [Abstract][Full Text] [Related]
52. Strategies for balancing internal and external validity in evaluations of interventions. Fredericks S; Sidani S; Fox M; Miranda J Nurse Res; 2019 Dec; 27(4):19-23. PubMed ID: 31578832 [TBL] [Abstract][Full Text] [Related]
53. Propensity score-integrated composite likelihood approach for augmenting the control arm of a randomized controlled trial by incorporating real-world data. Chen WC; Wang C; Li H; Lu N; Tiwari R; Xu Y; Yue LQ J Biopharm Stat; 2020 May; 30(3):508-520. PubMed ID: 32370640 [TBL] [Abstract][Full Text] [Related]
54. The Opportunities and Challenges of Pragmatic Randomized Trials Using a Specialized Software: CloudTrials Project. Fosser SM; Kamozin A; McDonald EG; Tamblyn R; Lee TC Stud Health Technol Inform; 2019 Aug; 264():1544-1545. PubMed ID: 31438223 [TBL] [Abstract][Full Text] [Related]